logo
Is lithium finding its wings again? Here's what three ASX explorers have to say

Is lithium finding its wings again? Here's what three ASX explorers have to say

News.com.au6 days ago
After prolonged depressed prices, lithium has begun to claw its way back
China continues to control the majority of lithium processing and EV manufacturing
Stockhead speaks to three explorers in the lithium space to gauge their thoughts
Lithium was a market darling in 2022, ushering in a tsunami of newly minted explorers to the ASX – then the wave crashed.
Now the beloved battery metal could be starting to swell again, with activity emerging in recent weeks.
The price of the battery-metal has spectacularly devalued over the past few years due to oversupply and re-adjusting Western demand for electric vehicles.
But now, the Global X Lithium & Battery Tech ETF has climbed more than 20% over the past month, whilst price reporting agency Fastmarkets on Tuesday assessed 6% Li2O – the benchmark for the spodumene concentrate mined by WA producers – at US$760/t.
That's a violent increase from the June 23 low of US$610/t, underpinned by rising futures prices in China and improved buying interest from battery makers, as well as the closure of a number of Chinese operations on environmental grounds.
In the same period, lithium carbonate has run from US$8050/t to US$8550/t.
This change has flowed through to ASX miners.
Kathleen Valley lithium mine owner Liontown Resources (ASX:LTR) has regularly been a barometer for speculative interest in the sector.
It once ran from 3c to more than $3 at lithium's highs before crashing below 60c at its recent ebb. The Gina Rinehart backed stock has seen its share price climb more than 16% over the past five days to breathe down the neck of $1 once again.
A tale of two countries
It isn't always easy to glean clear answers from the market (furiously shakes Magic 8 Ball).
But some of the most recent data has come out of two closely linked places, Africa's lithium hotspot of Zimbabwe and China.
This month, Zimbabwe reported a 30% growth in lithium exports for the first half of this year in spite of a weak spot price.
The Minerals Marketing Corporation of Zimbabwe says the country shipped nearly 600,000t of spodumene concentrate between January and June this year, an increase from more than 450,000t during the same period in the year prior.
China is the chief buyer of Africa's lithium, a source it has cultivated to garner control over a supply chain previously dominated at the raw material end by Australia and Chile.
And it remains top dog in the EV industry by the length of the straight, producing more than 70% of the world's share in 2024 with an even stronger grip on battery production and battery chemical refining.
Today, Chinese-owned companies commandeer about one quarter of the globe's lithium mining and two-thirds of battery grade lithium chemical capacity.
Low lithium prices have suited the dominant battery players CATL and BYD, who have developed their own mines in China to help flood the market and, allegedly, keep a lid on prices.
But the Chinese Government has become increasingly concerned with Neijuan, a phrase popularised by Weibo users to describe the negatives of the "rat race". In mining terms, it means authorities could crack down on sectors where competition is driving industrial losses.
Whether that was behind the closure of Zijin subsidiary Zangge Mining's Qinghai operations, a key factor in recent commodity price increases, is a subject of speculation.
Is this month's increase in the lithium price nothing but a dead cat bounce, or are we witnessing a return to glory days? While many explorers pivoted their attention away from the battery metal, Stockhead spoke to three companies who believe in the long term opportunity.
What are you seeing on the ground floor as a lithium explorer in terms of market sentiment?
Chariot Corporation (ASX:CC9) managing director Shanthar Pathmanathan: "I believe it's the beginning of a massive bull run in lithium, but it's important to be cost conscious. Africa has increased production from artisanal and small scale mines by 500% in the last three years whilst lithium prices crashed by 90%. African supply is now about 20% of world supply.
"Moreover, the Chinese buyers seem to prefer African supply. The inside lane in lithium for the next year or so while prices are still recovering will likely continue to be the Africa-to-China supply route. Getting in on the inside lane means making money whilst others are not and potentially taking advantage of opportunities elsewhere.
"I still see lithium as the great disruptor of the massive, multi-trillion dollar oil market and this recent crisis has given us the opportunity we needed to get positioned."
Pursuit Minerals (ASX:PUR) managing director and CEO Aaron Revelle: "We're seeing a definitive shift in sentiment on the ground. The rebound in lithium carbonate pricing has re-ignited some soft investor interest, particularly in high-quality brine assets following on from the Rio Tinto acquisition of Arcadium and many watching how the new CEO of Rio will advance those assets.
"There's more inbound interest, especially those looking to secure supply outside of China. Juniors with pilot scale production, strong grades, and a clear pathway to development are getting a second look. It's cautious optimism, but the tone has improved from earlier this year."
Delta Lithium (ASX:DLI) managing director James Croser: "There's perhaps a glimmer of dawn on the horizon after a very long night. I want to believe that this uptick in sentiment is a collective realisation that the tide may be on the turn and the relentless adoption of new battery technologies and applications, and persistent double digit growth in most markets will in fact translate into improved market pricing in the long run. I mean, how can it not? But I've been wide awake since midnight waiting for that dawn, seen a couple of false ones and we need to be cautious that our optimism isn't clouding our vision."
What potential catalysts are on the horizon that could create a boon in the lithium space?
SP: "Interest rate cuts and more dovish monetary policy is what I'm looking at. I think Trump is bang on the money in that it needs to flow again. Easier access to money will mean households will have more money to spend on relative luxury items like EVs, although the price gap has diminished or reversed as of late with the advent of the Chinese EVs."
AR: "Several key catalysts could trigger a strong re-rating across the lithium sector, such as a potential revival of EV subsidies in Europe or the US could direct significant capital toward EV supply chains in an effort to break China's dominance on processing. Rising investment in grid-scale battery storage, driven by the global rollout of renewable energy infrastructure and the ever growing rise of the AI sector is also emerging as another major demand driver.
"In China, recent signs of supply-side discipline – including Zangge Mining's decision to halt lithium production – highlights efforts to stabilise prices, and any further pro-EV or economic support measures from Beijing would add upward pressure.
"Finally, M&A activity remains a powerful catalyst; strategic acquisitions by automakers, battery manufacturers, or majors seeking to lock in supply are likely to drive a valuation reset across the developer end of the market."
JC: "On top of consistent EV demand growth, I think renewables and the associated fixed battery storage requirements are the dark horse. Having batteries on your business/house with solar on the roof is akin to putting a water tank next to a windmill. It's obvious that one complements the other. People are just getting over the novelty of solar, wait until everyone works out that having battery storage is like keeping the solar on all night!
"Politically, I think seeing serious downstream processing outside China by the Europeans/North Americans/Japanese will go a long way in breaking the pricing power that the Chinese now possess for lithium raw materials. That'll likely require government assistance at these prices, so I'll be looking for some firm government actions to back up the rhetoric and ultimately provide a broader customer base for the miners."
How do you view the future of global lithium demand, and which countries will lead the charge as China dominates EV production?
SP: "That will continue to be the trend. China is close to the great tipping point. One in two cars sold in China are EVs and they could move to close to 100% EV penetration soon. The USA EV sales will respond with more dovish monetary policy."
AR: "China remains dominant in battery manufacturing and electric vehicle production, currently selling over 1 million EVs per month, a staggering pace that has helped push global EV adoption to a tipping point, with one in every four new vehicles sold now electric.
"Whilst China leads today, we see a more diversified future emerging over the next 5–10 years. The US and Canada continue to invest heavily in scaling domestic EV and battery supply chains, with a growing focus on building out domestic critical mineral production and processing. Europe is similarly accelerating efforts to localise refining capacity and secure offtake agreements, aiming to reduce reliance on China amid tightening ESG and supply-chain transparency standards.
"On the supply side, Argentina and Australia remain critical players with Argentina offering tier-1 brine resources, increased judicial and regulatory certainty, low-cost extraction potential, and faster development pathways. Demand for lithium isn't disappearing; it's shifting regionally. This transition is fuelling a new wave of investment, and competition across the global battery materials landscape."
JC: "China doesn't look like it's giving up first place any time soon. They have really bet the farm on lithium and invested a huge amount of capital in the battery supply chain going back at least 10 years.
"There's a long way to go before EVs inevitably overtake vehicles on the road, so I expect growth and innovation in the EV sector to continue apace. There's pretty strenuous competition going on between the new Chinese car manufacturers and the old car companies, with new models coming out all the time. Competition is good for consumers, so I expect the product offering to improve and strong competition to persist. Global EV penetration looks almost certain to continue to grow: the genie is well and truly out of the bottle, and it's a pretty cool genie with more torque and less moving parts."
What are the key challenges and opportunities you foresee in the lithium market over the next 12 months?
SP: "We could have a scramble for lithium supply if the Chinese market passes the tipping point. Car purchases are subject to the network effect where people tend to follow their neighbours. China is currently the only market that matters and they're at 50% EV penetration.
"Chariot is well setup after this downturn. We have reacquired the Horizon property with a 10.2Mt LCE resource and taken a 66.667% stake in a magnificent portfolio of spodumene bearing projects in Nigeria in the most counter cyclical way possible."
AR: "The lithium sector continues to face real challenges over the next 12 months with ongoing price volatility and a significantly tighter capital environment making it increasingly difficult for developers to raise the funds needed to progress projects compared to other commodities such as gold or copper. Negative sentiment around spodumene oversupply continues to cloud investor outlook, even though brine based projects remain comparatively low cost and economically robust even at current price levels of between US$8-10,000/t for lithium carbonate.
"Despite these challenges, there are clear opportunities emerging. Juniors with pilot scale operations or near term development timelines, particularly in Argentina, are well positioned to attract offtake interest as buyers look to diversify. ESG aligned, low cost brine projects are gaining traction with Western partners, and any recovery in sentiment, or lithium demand could sharply re-rate quality assets that are development-ready.
"Companies that come out with massive production targets above 20,000tpa of new material without the balance sheet to support it or are NPV chasing to try and look good in the market will struggle to gain investor interest. Investors can see the demand piece for lithium remaining intact with demand set to hit near 3 million tonnes by 2030, however it's capital discipline and realistic scalable projects that will win out long term."
JC: "I feel a little relieved that Delta isn't trying to navigate this price trough as a producer. Our challenge at Delta is to position our business and manage capital effectively through the downturn, keep our projects ticking along and be ready to come out of the blocks when real improvement shows up."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ASX lifts as energy sector leads gains
ASX lifts as energy sector leads gains

Courier-Mail

time39 minutes ago

  • Courier-Mail

ASX lifts as energy sector leads gains

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Cheery start to the morning The ASX has started the day off with a quiet but positive open, dipping slightly at first before moving into positive territory. At the time of writing, we're up 0.17% in the first hour of trade. Energy is leading gains (+0.74%) alongside healthcare, consumer discretionary, staples and financials. Oil prices jumped 3.5% overnight to US$72.51 a barrel of brent as US President Trump threatened Russia with fresh sanctions should they fail to negotiate a ceasefire with Ukraine. Gold also ticked up 0.4% to US$3324 an ounce and iron ore appreciated 0.3% to US$98.98 a tonne as markets anticipated more thawing in US-China relations ahead of the next round of trade talks. Back on the ASX, the top 7 banks index is providing some support (+0.32%), while the ASX 200 Resources (-0.07%) and All Ords Gold (-0.03%) indices hover in vaguely negative territory and the All Tech retreats -0.76%. WINNERS Code Name Last % Change Volume Market Cap MX1 Micro-X Limited 0.084 35% 668310 $41,366,540 SFG Seafarms Group Ltd 0.002 33% 583466 $7,254,899 SP3 Specturltd 0.016 33% 3536664 $3,802,801 BSA BSA Limited 0.12 33% 4432767 $6,777,023 ECT Env Clean Tech Ltd. 0.0025 25% 4252072 $8,030,871 MOH Moho Resources 0.005 25% 880329 $2,981,656 PIM Pinnacleminerals 0.048 20% 298948 $1,818,533 H2G Greenhy2 Limited 0.019 19% 110000 $11,006,589 IPB IPB Petroleum Ltd 0.007 17% 11020 $4,238,418 M4M Macro Metals Limited 0.007 17% 325588 $23,864,505 In the news... Cold cathode x-ray technology specialist Micro-X (ASX:MX1) has tapped into a nationwide network of 700 hospitals, surgical centres and outpatient facilities with a new supply agreement through a major US healthcare provider, the first of its kind for the company. MX1 will provide its Rover Plus mobile radiology system to interested facilities over an initial agreement period of three years. The company is in discussions with a second major procurement group for a similar supply agreement. Remote surveillance company Spectur (ASX:SP3) increased both total revenue (+10%) and recurring revenue (+20%) year-on-year, bringing in positive operating cash flow of $263k for the financial year. SP3 has been aggressively restructuring in recent months, reducing staff costs from $970k in the third quarter to $715k in the fourth. The company also ramped up R&D spending in a move to upgrade cloud infrastructure and software systems. Pinnacle Minerals (ASX:PIM) is climbing despite launching a $1.76m share placement at $0.04 per share, a more than 25% discount on its intraday trading price of $0.054 a share. PIM is also offering a free attaching option at $0.08 each for every two shares subscribed for. The fresh capital will go to exploration programs at the Adina East project in Quebec next door to several significant lithium projects and Pinnacle's rare earth and heavy mineral sands projects in Australia. LAGGARDS Code Name Last % Change Volume Market Cap SCP Scalare Partners 0.14 -22% 15500 $7,530,304 CZN Corazon Ltd 0.002 -20% 4000000 $2,961,431 JAV Javelin Minerals Ltd 0.002 -20% 3415417 $15,630,562 AMS Atomos 0.005 -17% 31450 $7,290,111 SHE Stonehorse Energy Lt 0.005 -17% 100000 $4,106,610 ENT Enterprise Metals 0.003 -14% 150 $4,799,610 GTR Gti Energy Ltd 0.003 -14% 2271683 $13,029,292 M2R Miramar 0.0035 -13% 242500 $3,987,293 FHS Freehill Mining Ltd. 0.004 -11% 690000 $15,362,341 MPR Mpower Group Limited 0.008 -11% 43068 $3,093,330 This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Top 10 at 11: ASX positive after muted open as Micro-X nets first major US supply deal

Aussie shares near all-time high after inflation cools
Aussie shares near all-time high after inflation cools

Perth Now

timean hour ago

  • Perth Now

Aussie shares near all-time high after inflation cools

The local share market has spiked after softer-than-expected inflation paved the way for the Reserve Bank to cut rates next month. At lunchtime on Wednesday, the benchmark S&P/ASX200 index index was up 59.8 points, or 0.69 per cent, to 8,764.4, a level just 12 points away from its all-time high set two weeks ago. The broader All Ordinaries had gained 56.1 points, or 0.63 per cent, to 9,022.8. The ASX200 was already in the green but rose another 36 points in the hour after the Australian Bureau of Statistics released its June quarter consumer price index readout. That report showed that the RBA's preferred inflation metric, trimmed mean inflation, was 2.7 per cent in the year to June 30, in line with expectations but down from 2.9 per cent in the year to March 31. Headline inflation came in at 2.1 per cent, slightly under expectations of 2.2 per cent. Betashares chief economist David Bassanese, one of just a few economists who correctly predicted that the RBA wouldn't cut rates this month, said that an August rate cut was now a "done deal". He predicted further cuts in November and February. Eight of the ASX's 11 sectors were higher at midday, with utilities flat and energy and tech slightly lower. The heavyweight financial sector was the biggest mover, rising 1.0 per cent, with gains for all the big four banks. CBA had advanced 1.7 per cent, Westpac had climbed 1.3 per cent, NAB had added 1.0 per cent and ANZ had grown 0.7 per cent. In the mining sector, West African Resources had advanced 5.7 per cent after reporting its Kiaka goldmine in Burkina Faso was ramping up to full commercial operations after pouring its first gold on June 26. Lithium miner Pilbara and nickel, copper and cobalt miner IGO were going in opposite directions after releasing their own quarterly updates, with the former rising 5.2 per cent and the latter dropping 7.1 per cent. Mineral Resources, which likewise released quarterly figures, was up 2.9 per cent. Elsewhere in the sector, BHP had dipped 0.2 per cent and Rio Tinto had dropped 0.5 per cent, while Fortescue had grown 0.8 per cent. The Australian dollar was buying 65.19 US cents, from 65.25 US cents at 5pm on Tuesday.

Health Check: Opthea investors have $80m less to fight for after cash-burning quarter
Health Check: Opthea investors have $80m less to fight for after cash-burning quarter

News.com.au

timean hour ago

  • News.com.au

Health Check: Opthea investors have $80m less to fight for after cash-burning quarter

Eye drug developer Opthea's cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today's sector gains after a US deal with a mystery party The financial fallout from Opthea's (ASX:OPT) two failed eye disease trials has become starkly apparent. Despite ceasing its two pivotal phase III trials, Opthea recorded US$53.5 million ($82 million) of outflows in the June quarter. This takes residual cash to US$48.4 million, from US$101.4 million as at the end of March. The costs mainly related to the winding down of the Coast and Shore trials, for wet age-related macular degeneration. Each of them enrolled close to 1000 patients, so they were meaty studies. Following the March 24 trial bombshell, in April the company shed its workforce by 65%. In June four directors – half the board – departed. Future uncertain Under the terms of a development funding agreement (DFA), Opthea could owe investors somewhere between nothing and US$680 million. Given Opthea has US$170 million of debt, any bumper return would be hypothetical. Opthea 'remains in active negotiations with its DFA investors to deliver an outcome that is in the best interests of the company and its shareholders'. Opthea shares have not traded since the March disaster, so any passer-by from Mars would think they are still valued at 60 cents for a $738 million market cap. The only bright note is the company earned US$700,000 of interest. Microx shares surge on US deal Microx shares this morning went on a 33% share romp after the device maker announced a US customer for its Rover mobile X-ray units. The customer has requested anonymity, but it's a "top tier US healthcare group" that runs 700 hospitals. The company says the three year deal is subject to normal commercial conditions, but it does not quantify the expected revenue. Given the share surge, investors presume it's kinda, like, material. Polynovo shakes off The Troubles Wound repair house PolyNovo (ASX:PNV) has shrugged off corporate governance issues by reporting a strong recovery in revenue and profits. At its full-year results later next month, Polynovo should report sales of $118.6 million for the year to June 2025, up 30% year on year. Second (June) half cash flow swung to a positive $15.7 million, compared with a $12.5 million deficit in the first half. Management expects full-year earnings before interest tax depreciation and amortisation of $11.2-12.4 million. This compares with the previous year's $3.6 million. Of the revenue, $88.4 million derived from the US, up 29%. The company gleaned most of its sales from its flagship product, Novosorb BTM. 'I like to review the year and the go-forward from a high level and all I see is growth and opportunity,' chairman David Williams chirps. In mid-March the company said CEO Swami Raote would depart, amid claims of bullying and inappropriate behaviour against Williams. The board engaged independent lawyers to probe the claims. It also bought in former Westpac chairman Lindsay Maxsted to advise the board on governance matters. The unashamedly outspoken Williams denies any wrongdoing and like the Irish, The Troubles seem to be forgotten. Macquarie Equities similarly is enthused, ascribing a $2.45 per share valuation relative to yesterday's closing value of $1.22. 'We see several near-term positive catalysts for Polynovo, with a significant longer-term opportunity in additional indications.' Yesterday, peer Kiwi wound repair house Aroa Biosurgery (ASX:ARX) also found investor favour after reporting its third successive quarter of positive cash flow, of NZ$1.7 million. Aroa has guided to revenue of NZ$92-100 million for the year to March 2026, with normalised underlying earnings of NZ$5-8 million. Emvision's Emu trial is in full stride… Portable brain (stroke) detection device maker EMvision Medical Devices (ASX:EMV) says its pivotal trial to support FDA approval is 'progressing well'. Pertaining to the company's lightweight bedside unit Emu, the trial is recruiting up to 300 stroke patients across four US and two Australian high-volume stroke centres. A variant for road and air ambulances, First Responder has been trialled by the Royal Flying Doctor Service. A Melbourne stroke ambulance has also had a look-see. Emvision recorded June quarter outflows of $2 million, taking cash to $10.5 million. But the company will benefit from a non-dilutive $5 million grant from the Industry Growth Program, to develop First Responder. The aforementioned Microx is also developing a portable head CT scanner to diagnose strokes. … while Actinogen's trial recruitment passes halfway mark Actinogen Medical (ASX:ACW) reports that its keenly anticipated phase 2b/3 Alzheimer's disease study has enrolled 123 of the targeted 220 patients. Dubbed Xanamia, the trial has recruited across 20 US and 15 Australian sites, targeting patients with mild to moderate progressive Alzheimer's. Actinogen's compound Xanamem targets elevated levels of a protein called pTau181. The novel mechanism of action inhibits production of cortisol, which is toxic to the brain in excessive amounts. Having recruited its 100 th patient, Xanamia is subject to an interim 'futility' review next January. This will determine whether the trial is worth continuing. With Xanamia hotting up, Actinogen disclosed June quarter cash outflows of $5.1 million, leaving June-end cash of $16.5 million. The company also has access to a $3 million loan, the first component of a $13.8 million advance of expected research and development tax incentives. Often a supplement to equity raisings, R&D loans have become increasingly popular with biotechs seeking to bring forward cash flow. Ozempic maker's fat profits become thinner The fate of Europe's biggest drug maker shows that boom conditions in the drug-making game rarely last – even with miracle fat-busting drugs. The maker of the anti-obesity and diabetes drugs Ozempic and Wegovy, Denmark's Novo Nordisk overnight issued a profit warning that sent the shares tumbling up to 28% on the Nasdaq Copenhagen exchange. The company slashed its outlook for 2025 sales growth to between 8-14%, from between 13-21% previously. According to Reuters, sales have been affected by custom-made compounded drugs that emulate the branded versions. The US bars pharmacies from replicating approved drugs, but allows 'compounding' for patients needing custom doses or formulations. Dial 'L' for loophole. The company also faces turmoil from the abrupt removal in May of CEO Lars Fruergaard Jorgensen. The board replaced him with veteran insider Maziar Mike Doustdar. Slowing fat drug sales aside, Doustdar also faces the prospect of a 15% tariff on goods imported into the US. 'We need to increase the sense of urgency and execute differently,' Doustdar told investors. Sounds about right.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store